Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
FibroGen Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
FGEN
Nasdaq
8731
https://www.fibrogen.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for FibroGen Inc
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
- Mar 28th, 2024 3:01 pm
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
- Mar 27th, 2024 12:50 pm
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
- Mar 26th, 2024 11:00 am
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
- Mar 20th, 2024 7:45 pm
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
- Mar 20th, 2024 3:46 pm
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
- Mar 20th, 2024 9:38 am
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
- Mar 19th, 2024 12:49 pm
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
- Mar 14th, 2024 12:23 pm
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
- Mar 12th, 2024 3:06 pm
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
- Mar 11th, 2024 11:00 am
Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
- Mar 11th, 2024 10:59 am
FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 1:09 pm
US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results
- Feb 29th, 2024 12:21 pm
FibroGen Full Year 2023 Earnings: Misses Expectations
- Feb 28th, 2024 11:54 am
Q4 2023 FibroGen Inc Earnings Call
- Feb 27th, 2024 2:59 pm
FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023
- Feb 26th, 2024 9:40 pm
UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca
- Feb 26th, 2024 9:34 pm
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 26th, 2024 9:06 pm
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
- Feb 26th, 2024 9:05 pm
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
- Feb 20th, 2024 12:00 pm
Scroll